Philip Young photo

ALTERNATIVE INVESTMENTS, BIOTECH

Philip Young

CEO and Director,

Lobe Sciences

  • CEO and Director, Lobe Sciences

About Philip

Phil Young is an analytical and result-driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a director and chief executive officer for public companies for the past 20 years creating significant shareholder value.

Philip's Videos

Lobe Sciences is a life sciences company focused on developing sub-psychedelic doses of psychedelic medicines targeting the 5-HT2A receptor. The company, through collaborations with industry-leading partners, is engaged in drug research and development using derivatives of psychedelic compounds to improve brain and mental health and wellness. Phil Young will provide an overview, scientific focus and development plans for 2023 and beyond and update the most recent exciting developments for their upcoming trials.

Lobe Sciences is a life sciences company focused on developing sub-psychedelic doses of psychedelic medicines targeting the 5-HT2A receptor. The company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds in conjunction with NAC (N-acetyl cysteine) to improve brain and mental health and wellness. Phil Young will provide an overview, scientific focus and development plans for 2022 and beyond.

Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Lobe Sciences' goal is to change that fact, and during this presentation, Philip Young, CEO and director, will outline a path for the development of therapeutics for which the company intends to seek FDA approval in the United States, and similar approvals internationally.